NCT02607085 (REVEAL-ED) is a clinical trial in Hyperkalemia, sponsored by ZS Pharma, Inc..

Who is sponsoring NCT02607085?

NCT02607085 is sponsored by ZS Pharma, Inc..

What condition does NCT02607085 study?

NCT02607085 studies Hyperkalemia.

Is NCT02607085 still recruiting?

NCT02607085 is currently completed. Last updated 8 June 2017.

Last reviewed 2017-06-08 · How we verify

NCT02607085: REVEAL-ED

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

REal World EVidence for TrEAtment of HyperkaLemia in Emergency Department: Multicenter, Prospective, Observational Study

Completed Last updated 8 June 2017

What this trial tests

trial in Hyperkalemia in 203 participants. Completed in 31 May 2016.

Timeline

31 October 2015

Primary endpoint
30 April 2016

31 May 2016

Quick facts

Lead sponsor	ZS Pharma, Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	203
Start date	31 October 2015
Primary completion	30 April 2016
Estimated completion	31 May 2016
Sites	8 locations across United States

Conditions studied

Hyperkalemia — all drugs for Hyperkalemia →

Sponsor

ZS Pharma, Inc. — full company profile →

Who can join

18 and older, any sex, with Hyperkalemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the management of subjects with Standard of Care (SOC) when admitted to the Emergency Department (ED) with hyperkalemia (potassium value ≥ 5.5 mmol/L). Demographics and medical history data, including previous ED visits and/or hospital admissions for hyperkalemia and reason for current ED admission, will be recorded. Subjects who receive an intervention/treatment for hyperkalemia will have study-related potassium values determined at 30 minutes, 1, 2, and 4 hours after the start of treatment. Subjects who receive no intervention/treatment during the initial 4-hour period will have a study-related potassium value determined 4 hours after the baseline potassium measurement. Available data obtained as part of SOC management will include physical examinations, vital signs, fluid intake and urine output, ECGs, clinical laboratory data, and results of chest x-rays. Data regarding the subject's chief complaint upon admission to the ED, the possible cause of the subject's hyperkalemia, and admitting and discharge diagnosis will be recorded; the subject's overall discharge summary will also be collected.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE).
Peacock WF, Rafique Z, Vishnevskiy K, Michelson E, et al · · 2020 · cited 57× · PMID 32149451 · DOI 10.1111/acem.13954
Study design of Real World Evidence for Treatment of Hyperkalemia in the Emergency Department (REVEAL-ED): a multicenter, prospective, observational study.
Rafique Z, Kosiborod M, Clark CL, Singer AJ, et al · · 2017 · cited 4× · PMID 29026889 · DOI 10.15441/ceem.17.207
Net clinical benefit of patiromer for acute hyperkalemia: a post-hoc analysis of the reduce trial.
McArthur R, Peacock WF, Budden J, Rafique Z. · · 2025 · PMID 41178555 · DOI 10.1080/07853890.2025.2581912

Verify or expand the search:

Other recruiting trials for Hyperkalemia

Currently open trials in the same condition.

NCT06366230 — Adding Urea to the Final Dialysis Fluid · Phase 1, PHASE2 · recruiting
NCT06884267 — Hyperkalemia Quality Improvement Program (HK-QIP) Study · NA · recruiting
NCT06940414 — Prevalence and Risk Factors of Hyperkalemia in Non-Dialysis Chronic Kidney Disease Patients in Community · recruiting
NCT05766839 — Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age · Phase 2 · recruiting
NCT06365684 — Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4 · Phase 4 · recruiting

Other ZS Pharma, Inc. trials

Trials by the same sponsor.

NCT02609841 — POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study · completed
NCT02163499 — Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months · Phase 3 · completed
NCT02107092 — Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia. · Phase 3 · completed
NCT02088073 — Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia. · Phase 3 · completed
NCT01737697 — Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02607085 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ZS Pharma, Inc.
Last refreshed: 8 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02607085.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing